TABLE 2.
Safety or laboratory parameter | No. (%) of animals |
||
---|---|---|---|
Control (n = 6) | Linezolid (n = 6) | Telavancin (n = 6) | |
Skin rash | 0 (0) | 0 (0) | 0 (0) |
Bronchospasm | 0 (0) | 0 (0) | 0 (0) |
Diarrhea | 0 (0) | 0 (0) | 0 (0) |
Vomiting | 0 (0) | 0 (0) | 0 (0) |
Hb reductiona | 1 (16.7) | 0 (0) | 0 (0) |
Platelet count reductiona | 2 (33.7) | 3 (50.0) | 1 (16.7) |
ALT level > ULN | 1 (16.7) | 2 (33.7) | 1 (16.7) |
Alkaline phosphatase level > 2× ULN | 1 (16.7) | 1 (16.7) | 0 (0) |
Abnormal potassium levelb | 1 (16.7) | 1 (16.7) | 0 (0) |
Creatinine level increasec | 0 (0) | 4 (66.7) | 1 (16.7) |
Creatinine level of >1.5 mg/dl | 1 (16.7) | 4 (66.7) | 0 (0) |
Urinary output reductiond | 2 (33.7) | 2 (33.7) | 0 (0) |
Furosemide administration | 3 (50.0) | 4 (66.7) | 0 (0) |
At least a 30% reduction from the value at pneumonia diagnosis.
Potassium level of <3.5 or >5.5 meq/liter.
Serum creatinine level increase of ≥25% from that at pneumonia diagnosis.
Urinary output of ≤0.5 ml · h/kg.
Hb, hemoglobin; ALT, alanine aminotransferase; ULN, upper limit of normal.